Unit of Forensic Toxicology (UoFT), Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Italy.
National Centre on Addiction and Doping, Istituto Superiore di Sanita, Rome, Italy.
Curr Neuropharmacol. 2018;16(1):84-96. doi: 10.2174/1570159X15666170828162057.
The effects of drugs on driving performance should be checked with drug concentration in the brain and at the same time with the evaluation of both the behavioural and neurophysiological effects. The best accessible indicator of this information is the concentration of the drug and/or metabolites in blood and, to a certain extent, oral fluid. We sought to review international studies on correlation between blood and oral fluid drug concentrations, neurological correlates and cognitive impairment in driving under the influence of drugs.
Relevant scientific articles were identified from PubMed, Cochrane Central, Scopus, Web of Science, Science Direct, EMBASE up to April 2017.
Up to 2010, no epidemiological studies were available on this matter and International scientists suggested that even minimal amounts of parent drugs in blood and oral fluid could affect driving impairment. More recently, epidemiological data, systematic reviews and meta-analysis on drugged drivers allowed the suggestion of impairment concentration limits for the most common illicit drugs. These values were obtained comparing driving disability induced by psychotropic drugs with that of established blood alcohol limits. Differently from ethyl alcohol where both detection methods and concentration limits have been well established even with inhomogeneity of ranges within different countries, in case of drugs of abuse no official cut-offs have yet been established, nor any standardized analytical protocols.
Multiple aspects of driving performance can be differently affected by illicit drugs, and even if for few of them some dose/concentration dependent impairment has been reported, a wider knowledge on concentration/impairment relationship is still missing.
药物对驾驶表现的影响应该通过脑内药物浓度和行为及神经生理效应的评估来检查。最容易获得这些信息的指标是血液中药物和/或代谢物的浓度,以及在一定程度上的唾液浓度。我们试图回顾国际上关于血液和唾液中药物浓度、神经相关和药物影响下驾驶认知障碍之间相关性的研究。
从 2017 年 4 月之前的 PubMed、Cochrane 中心、Scopus、Web of Science、Science Direct 和 EMBASE 中确定了相关的科学文章。
截至 2010 年,关于这个问题还没有流行病学研究,国际科学家建议即使血液和唾液中存在微量的母体药物,也可能会影响驾驶损伤。最近,对吸毒司机的流行病学数据、系统评价和荟萃分析允许对最常见的非法药物的损伤浓度限制提出建议。这些值是通过将精神药物引起的驾驶障碍与已确立的血液酒精限制进行比较得出的。与已经确立了检测方法和浓度限制,甚至在不同国家范围内也有不均匀性的乙基酒精不同,在滥用药物的情况下,还没有确定任何官方的截止值,也没有任何标准化的分析协议。
驾驶表现的多个方面可能会受到非法药物的不同影响,尽管对于其中一些药物,已经报告了一些剂量/浓度依赖性损伤,但对于浓度/损伤关系的了解仍然有限。